Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025262368> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3025262368 abstract "To investigate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for locally advanced or metastatic non-small cell lung cancer (NSCLC) as second-line chemotherapy.We retrospectively reviewed the treatment of 34 patients with advanced NSCLC whose first-line treatment had failed. These patients received nab-paclitaxel 260 mg/m2 on day 1 and day 8 of a 21-day cycle from July 2014 to February 2016. One cycle of treatment lasted 3 weeks and all patients completed more than two cycles. All patients were assessed for adverse events related to treatment.No patient achieved complete response (CR); 12 patients reached partial response (PR), 12 patients achieved stable disease (SD) and 10 patients progressive disease (PD). The overall response rate (ORR) was 35.3% and the disease control rate (DCR) 70.6 %. There was no significant difference in either ORR or DCR within the subgroups. The median progression-free survival (PFS) was 5.7 months (95% confidence interval (CI)=3.8-7.6) and the median overall survival (OS) was 9 months (95% CI=8.3-9.7). There was no statistical difference in OS (p=0.066), but subgroup analysis showed that patients with squamous carcinoma benefited more in PFS (the median PFS of squamous carcinoma vs. adenocarcinoma was 7.3 months vs. 5 months, p=0.001). Major adverse events included myelosuppression, gastrointestinal response, baldness, myalgia and neurotoxicity. Hypersensitivity reactions were not reported.Nab-paclitaxel is an effective chemotherapy for locally advanced and metastatic NSCLC as treatment and has a superior application prospect for squamous NSCLC. Toxicity is generally mild and manageable." @default.
- W3025262368 created "2020-05-21" @default.
- W3025262368 creator A5018304475 @default.
- W3025262368 creator A5021196919 @default.
- W3025262368 creator A5021242356 @default.
- W3025262368 creator A5035266722 @default.
- W3025262368 creator A5037567740 @default.
- W3025262368 creator A5070503844 @default.
- W3025262368 date "2017-07-20" @default.
- W3025262368 modified "2023-10-17" @default.
- W3025262368 title "Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer" @default.
- W3025262368 doi "https://doi.org/10.21873/anticanres.11873" @default.
- W3025262368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28739772" @default.
- W3025262368 hasPublicationYear "2017" @default.
- W3025262368 type Work @default.
- W3025262368 sameAs 3025262368 @default.
- W3025262368 citedByCount "7" @default.
- W3025262368 countsByYear W30252623682017 @default.
- W3025262368 countsByYear W30252623682019 @default.
- W3025262368 countsByYear W30252623682020 @default.
- W3025262368 countsByYear W30252623682022 @default.
- W3025262368 countsByYear W30252623682023 @default.
- W3025262368 crossrefType "journal-article" @default.
- W3025262368 hasAuthorship W3025262368A5018304475 @default.
- W3025262368 hasAuthorship W3025262368A5021196919 @default.
- W3025262368 hasAuthorship W3025262368A5021242356 @default.
- W3025262368 hasAuthorship W3025262368A5035266722 @default.
- W3025262368 hasAuthorship W3025262368A5037567740 @default.
- W3025262368 hasAuthorship W3025262368A5070503844 @default.
- W3025262368 hasBestOaLocation W30252623681 @default.
- W3025262368 hasConcept C121608353 @default.
- W3025262368 hasConcept C126322002 @default.
- W3025262368 hasConcept C141071460 @default.
- W3025262368 hasConcept C143998085 @default.
- W3025262368 hasConcept C197934379 @default.
- W3025262368 hasConcept C2776256026 @default.
- W3025262368 hasConcept C2776694085 @default.
- W3025262368 hasConcept C2776907518 @default.
- W3025262368 hasConcept C2777292972 @default.
- W3025262368 hasConcept C2778822529 @default.
- W3025262368 hasConcept C2779984678 @default.
- W3025262368 hasConcept C71924100 @default.
- W3025262368 hasConcept C90924648 @default.
- W3025262368 hasConceptScore W3025262368C121608353 @default.
- W3025262368 hasConceptScore W3025262368C126322002 @default.
- W3025262368 hasConceptScore W3025262368C141071460 @default.
- W3025262368 hasConceptScore W3025262368C143998085 @default.
- W3025262368 hasConceptScore W3025262368C197934379 @default.
- W3025262368 hasConceptScore W3025262368C2776256026 @default.
- W3025262368 hasConceptScore W3025262368C2776694085 @default.
- W3025262368 hasConceptScore W3025262368C2776907518 @default.
- W3025262368 hasConceptScore W3025262368C2777292972 @default.
- W3025262368 hasConceptScore W3025262368C2778822529 @default.
- W3025262368 hasConceptScore W3025262368C2779984678 @default.
- W3025262368 hasConceptScore W3025262368C71924100 @default.
- W3025262368 hasConceptScore W3025262368C90924648 @default.
- W3025262368 hasLocation W30252623681 @default.
- W3025262368 hasLocation W30252623682 @default.
- W3025262368 hasOpenAccess W3025262368 @default.
- W3025262368 hasPrimaryLocation W30252623681 @default.
- W3025262368 hasRelatedWork W1559201260 @default.
- W3025262368 hasRelatedWork W2085889668 @default.
- W3025262368 hasRelatedWork W2170590308 @default.
- W3025262368 hasRelatedWork W2244084663 @default.
- W3025262368 hasRelatedWork W2383259583 @default.
- W3025262368 hasRelatedWork W2587353874 @default.
- W3025262368 hasRelatedWork W2943367773 @default.
- W3025262368 hasRelatedWork W3031381806 @default.
- W3025262368 hasRelatedWork W4282826144 @default.
- W3025262368 hasRelatedWork W3107537753 @default.
- W3025262368 isParatext "false" @default.
- W3025262368 isRetracted "false" @default.
- W3025262368 magId "3025262368" @default.
- W3025262368 workType "article" @default.